MR
Therapeutic Areas
Wockhardt Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Zaynich (WCK 5222) | cUTI, HABP/VABP caused by MDR Gram-negative bacteria | NDA Filed |
| WCK 5153 | Resistant Gram-negative infections | Phase I |
| Zoliflodacin | Uncomplicated Gonorrhea | Phase III |
| WCK 4282 | Resistant Hospital-Acquired Infections | Preclinical/Phase I |
| Biosimilar Insulin Glargine | Diabetes Mellitus | Launched |
| Biosimilar Insulin Aspart | Diabetes Mellitus | Launched |
Leadership Team at Wockhardt
DH
Dr. Habil F. Khorakiwala
Founder and Chairman
DM
Dr. Murtaza Khorakiwala
Managing Director
DZ
Dr. Zoher Sihorwala
Senior Vice President and Head – Drug Regulatory Affairs
DV
Dr. Vinod Ahirrao
Senior Group Leader - Analytical Chemistry, Drug Discovery Research